UB Paderborn / Katalog / Suche / in CDI

A randomized, phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC)

Annals of oncology, 2009-06, Vol.20 (6), p.1068-1073

2009

Volltextzugriff (PDF)

Comparable Survival After Unrelated and Related Allogeneic Stem Cell Transplantation Performed at Community Cancer Centers

Biology of blood and marrow transplantation, 2012, Vol.18 (2), p.S348-S349

2012

Volltextzugriff (PDF)

Anti-epidermal growth factor (EGFR) antibody, cetuximab, in patients with stage IV colorectal carcinoma who failed all standard therapy: Final report of an access protocol

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.3646-3646

2005

Volltextzugriff (PDF)

Randomized phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2007-06, Vol.25 (18_suppl), p.7586-7586

2007

Volltextzugriff (PDF)

HLA-DR histocompatibility leukocyte antigens permit cultured human melanoma cells from early but not advanced disease to stimulate autologous lymphocytes

The Journal of clinical investigation, 1984-01, Vol.73 (1), p.267-271

1984

Volltextzugriff (PDF)

Abstract S1-02: Final analysis of a phase II 3-arm randomized trial of neoadjuvant trastuzumab or lapatinib or the combination of trastuzumab and lapatinib, followed by six cycles of docetaxel and carboplatin with trastuzumab and/or lapatinib in patients with HER2+ breast cancer (TRIO-US B07)

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.S1-S1-02

2013

Volltextzugriff (PDF)

Use of a viral lysate of melanoma cells in patients with metastatic melanoma to lymph nodes

Cancer, 1984-05, Vol.53 (10), p.17A-17A

Zehngebot, L M

1984

Volltextzugriff (PDF)

Anti-epidermal growth factor (EGFR) antibody cetuximab in patients with stage IV colorectal carcinoma who failed all standard therapy: An Access Protocol

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.3753-3753

2004

Volltextzugriff (PDF)

Anti-epidermal growth factor (EGFR) antibody cetuximab in patients with stage IV colorectal carcinoma who failed all standard therapy: An Access Protocol

Journal of clinical oncology, 2004-07, Vol.22 (14_suppl), p.3753-3753

2004

Volltextzugriff (PDF)

Abstract P1-11-12: Phase II Trial of Presurgical Treatment with Trastuzumab (H) or Lapatinib (Ty) or the Combination of Trastuzumab and Lapatinib (H+Ty), Followed by Six Cycles of Docetaxel (T) and Carboplatin (C) with Trastuzumab (TCH) or Lapatinib (TCTy) or the Combination of Trastuzumab and Lapatinib (TCHTy) in Patients with HER2+ Breast Cancer

Cancer research (Chicago, Ill.), 2010-12, Vol.70 (24_Supplement), p.P1-P1-11-12

2010

Volltextzugriff (PDF)

Invasive malignant melanomas lacking competence for metastasis

The American journal of dermatopathology, 1984, Vol.6 Suppl, p.55-61

1984

Volltextzugriff (PDF)

Functional consequence of variation in melanoma antigen expression

Cancer Immunology, Immunotherapy, 1983-10, Vol.16 (1), p.30-34

1983

Volltextzugriff (PDF)

Long term response in a patient with neoplastic meningitis secondary to melanoma treated with (131)I-radiolabeled antichondroitin proteoglycan sulfate Mel-14 F(ab')(2): a case study

Cancer, 2001-05, Vol.91 (9), p.1809

2001

Volltextzugriff (PDF)

The role of lymph node dissection for clinical stage I malignant melanoma of intermediate thickness (1.51—3.99 mm)

Cancer, 1985-07, Vol.56 (2), p.413-418

1985

Volltextzugriff (PDF)

Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)

Nature communications, 2020-11, Vol.11 (1), p.5824-15, Article 5824

2020

Volltextzugriff (PDF)

Chemotherapy for squamous cell carcinoma of the head and neck: A progress report

American journal of otolaryngology, 1980-08, Vol.1 (4), p.306-323

1980

Volltextzugriff (PDF)

HLA-DR histocompatibility leukocyte antiges permit cultured human melanoma cells from early but not advanced disease to stimulate autologous lymphocytes

The Journal of clinical investigation, 1984, Vol.73 (1), p.267-271

1984

Volltextzugriff (PDF)

Bortezomib and Pegylated Liposomal Doxorubicin as Induction Therapy for Adult Patients with Symptomatic Multiple Myeloma: Cancer and Leukemia Group B Study 10301

Blood, 2006-11, Vol.108 (11), p.797-797

2006

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

A randomized, phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC)

Comparable Survival After Unrelated and Related Allogeneic Stem Cell Transplantation Performed at Community Cancer Centers

Anti-epidermal growth factor (EGFR) antibody, cetuximab, in patients with stage IV colorectal carcinoma who failed all standard therapy: Final report of an access protocol

Randomized phase II trial of two dose schedules of carboplatin/paclitaxel/cetuximab in stage IIIB/IV non-small cell lung cancer (NSCLC)

HLA-DR histocompatibility leukocyte antigens permit cultured human melanoma cells from early but not advanced disease to stimulate autologous lymphocytes

Abstract S1-02: Final analysis of a phase II 3-arm randomized trial of neoadjuvant trastuzumab or lapatinib or the combination of trastuzumab and lapatinib, followed by six cycles of docetaxel and carboplatin with trastuzumab and/or lapatinib in patients with HER2+ breast cancer (TRIO-US B07)

Use of a viral lysate of melanoma cells in patients with metastatic melanoma to lymph nodes

Anti-epidermal growth factor (EGFR) antibody cetuximab in patients with stage IV colorectal carcinoma who failed all standard therapy: An Access Protocol

Anti-epidermal growth factor (EGFR) antibody cetuximab in patients with stage IV colorectal carcinoma who failed all standard therapy: An Access Protocol

Invasive malignant melanomas lacking competence for metastasis

Functional consequence of variation in melanoma antigen expression

Long term response in a patient with neoplastic meningitis secondary to melanoma treated with (131)I-radiolabeled antichondroitin proteoglycan sulfate Mel-14 F(ab')(2): a case study

The role of lymph node dissection for clinical stage I malignant melanoma of intermediate thickness (1.51—3.99 mm)

Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07)

Chemotherapy for squamous cell carcinoma of the head and neck: A progress report

HLA-DR histocompatibility leukocyte antiges permit cultured human melanoma cells from early but not advanced disease to stimulate autologous lymphocytes

Bortezomib and Pegylated Liposomal Doxorubicin as Induction Therapy for Adult Patients with Symptomatic Multiple Myeloma: Cancer and Leukemia Group B Study 10301

Suchergebnisse filtern